Imunon (NASDAQ:IMNN) Trades 5.6% Higher

The shares of Imunon, Inc. (NASDAQ:IMNN – Get Free Report ) rose 5.6% on Tuesday. The company traded as low as $1.15 and last traded at $1.14. About 294,313 shares were traded during trading, down 74% from the average daily volume of 1,151,619 shares. Shares previously closed at $1.08.

Analyst upgrades and downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Imunon in a report on Thursday, August 15th.

Check out our latest research report on Imunon

Imunon stock performance

The stock has a 50-day moving average of $1.22 and a 200-day moving average of $1.25. The company has a market cap of $10.06 million, a PE ratio of -0.53 and a beta of 2.13.

Imunon (NASDAQ:IMNN – Get Your Free Report ) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.04. Equities research analysts forecast that Imunon, Inc. will post -1.71 EPS for the current year.

About Imunon

(Get a free report)

Imunon, Inc., a clinical-stage biotechnology company, is engaged in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer, which is in Phase II clinical development.

See Also

Get news and reviews for Imunon Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Imunon and related companies with MarketBeat.com ‘s FREE daily email newsletter.